Find Locnartecan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Locnartecan, Hdc sn-38, Pen-866, 1472614-83-7, Sta 12-8666, Sdc-trap 0063
Molecular Formula
C49H49N7O9
Molecular Weight
880.0  g/mol
InChI Key
QTPZAEAYDWMVJO-GGCSAXROSA-N
FDA UNII
56DL1J49LR

Locnartecan
Locnartecan is a miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.
1 2D Structure

Locnartecan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1H-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate
2.1.2 InChI
InChI=1S/C49H49N7O9/c1-5-31-33-20-30(8-9-38(33)50-43-35(31)24-55-40(43)22-37-36(45(55)59)25-64-46(60)49(37,63)6-2)65-48(62)54-16-12-27(13-17-54)11-15-53-18-14-28-19-29(7-10-39(28)53)56-44(51-52-47(56)61)34-21-32(26(3)4)41(57)23-42(34)58/h7-10,14,18-23,26-27,57-58,63H,5-6,11-13,15-17,24-25H2,1-4H3,(H,52,61)/t49-/m0/s1
2.1.3 InChI Key
QTPZAEAYDWMVJO-GGCSAXROSA-N
2.1.4 Canonical SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C
2.1.5 Isomeric SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C
2.2 Other Identifiers
2.2.1 UNII
56DL1J49LR
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Sta-12-8666

2. Sta-8666

2.3.2 Depositor-Supplied Synonyms

1. Locnartecan

2. Hdc Sn-38

3. Pen-866

4. 1472614-83-7

5. Sta 12-8666

6. Sdc-trap 0063

7. 56dl1j49lr

8. Hsp90-targeted Sn-38 Conjugate Pen-866

9. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1h-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate

10. Locnartecan [inn]

11. Pen866

12. Chembl4297475

13. Pen-866 [who-dd]

14. Schembl15522240

15. Schembl22223739

16. Sta-8666

17. Sb19799

18. (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-(propan-2-yl)phenyl)-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)piperidine-1-carboxylate

19. 1-piperidinecarboxylic Acid, 4-(2-(5-(3-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)-, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl

20. 1-piperidinecarboxylic Acid, 4-(2-(5-(3-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)-, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 880.0 g/mol
Molecular Formula C49H49N7O9
XLogP35.4
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count11
Rotatable Bond Count10
Exact Mass879.35917617 g/mol
Monoisotopic Mass879.35917617 g/mol
Topological Polar Surface Area199 Ų
Heavy Atom Count65
Formal Charge0
Complexity1980
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 1472614-83-7 / PEN-866 API manufacturers, exporters & distributors?

PEN-866 manufacturers, exporters & distributors 1

63

PharmaCompass offers a list of PEN-866 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right PEN-866 manufacturer or PEN-866 supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred PEN-866 manufacturer or PEN-866 supplier.

PharmaCompass also assists you with knowing the PEN-866 API Price utilized in the formulation of products. PEN-866 API Price is not always fixed or binding as the PEN-866 Price is obtained through a variety of data sources. The PEN-866 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

PEN-866

Synonyms

Locnartecan, Hdc sn-38, 1472614-83-7, Sta 12-8666, Sdc-trap 0063, 56dl1j49lr

Cas Number

1472614-83-7

Unique Ingredient Identifier (UNII)

56DL1J49LR

About PEN-866

Locnartecan is a miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.

Locnartecan Manufacturers

A Locnartecan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Locnartecan, including repackagers and relabelers. The FDA regulates Locnartecan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Locnartecan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Locnartecan Suppliers

A Locnartecan supplier is an individual or a company that provides Locnartecan active pharmaceutical ingredient (API) or Locnartecan finished formulations upon request. The Locnartecan suppliers may include Locnartecan API manufacturers, exporters, distributors and traders.

Locnartecan GMP

Locnartecan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Locnartecan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Locnartecan GMP manufacturer or Locnartecan GMP API supplier for your needs.

Locnartecan CoA

A Locnartecan CoA (Certificate of Analysis) is a formal document that attests to Locnartecan's compliance with Locnartecan specifications and serves as a tool for batch-level quality control.

Locnartecan CoA mostly includes findings from lab analyses of a specific batch. For each Locnartecan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Locnartecan may be tested according to a variety of international standards, such as European Pharmacopoeia (Locnartecan EP), Locnartecan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Locnartecan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty